NuScale Power (SMR) Q3 2026 Earnings Call Transcript

NuScale reported Q3 2026 revenue of $0.3 million, down from $8.2 million a year earlier after RoPower FEED Phase 2 work ended, while net loss narrowed to $45.7 million from $532.6 million and operating expenses fell to $65 million from $549 million. Liquidity increased to $1.9 billion from $916 million, supporting long-lead inventory and fabrication after a Doosan Enerbility agreement for first-article reactor-module components. The manufacturing milestone advances readiness, but TVA-related commercial commitments remain unfinalized, suppliers require firm orders for some tooling, and management provided no revenue or expense guidance.

Analysis

The key valuation question is whether SMR’s preparation spend converts into contracted, recoverable inventory—not whether a first component can be fabricated. The first-article work may expose design and quality issues early, but it does not establish a series-production cost curve, an end-customer schedule, or a binding module sale. Management clarified that a TVA PPA would be an intermediate step: engineering/licensing work and a separate NuScale–ENTRA1 OEM agreement still follow. That leaves a potentially long gap between headline project progress and material module revenue.

Liquidity reduces near-term financing pressure, but work-in-process is cash committed ahead of orders, not equivalent to cash available for other uses. Track quarterly cash conversion, WIP growth, and whether supplier tooling actually starts against firm commitments. Supplier reluctance to tool without orders is the bottleneck behind the manufacturing narrative; Doosan progress may help unlock suppliers, but only customer contracts can validate repeatable demand. Romania is an additional source of optionality, not a dependable near-term offset while government direction remains unclear.

Near term, the manufacturing announcement can support sentiment, while essentially absent revenue leaves the equity highly sensitive to project headlines and risk appetite. Over 1–3 months, the decisive catalyst is contract sequencing and specificity, not another readiness milestone. Over 6–18 months, successful first-article completion plus binding orders could improve execution credibility; delays, cost overruns, or continued inventory build without orders would weaken the thesis. Contrarian point: treating liquidity as proof of commercial de-risking conflates runway with demand. The bullish thesis is falsified by stalled PPA/OEM progress alongside rising WIP or cash burn; it strengthens only with binding commitments and disclosed unit economics.

Key Decisions for Investors

• Do not chase the manufacturing milestone as standalone evidence of commercialization. Keep SMR on an event-driven watchlist; consider a small, risk-capped long only after a binding OEM order or clearly funded customer commitment, rather than on a PPA headline alone.
• Set alerts for TVA/ENTRA1 contract terms, supplier tooling starts, first-article acceptance, quarterly WIP and cash-flow changes, and any initial module-margin disclosure. A PPA without a subsequent OEM agreement is not the demand confirmation the equity needs.
• If holding SMR, size it as a long-duration execution option rather than on near-term earnings: revenue visibility remains limited, while inventory can absorb cash before sales. Reassess if WIP rises materially without contract milestones, liquidity trends down faster than planned, or first-article timing slips.
• No pair or options trade is warranted from this call alone: valuation, current positioning, implied volatility, and the timing of customer decisions are not provided. A sustained stall in contracting despite additional readiness claims would be a thesis-negative signal.